Biomarker Technology

Clinically Validated and Proprietary

The OncAlert™ Labs OraMark™ Test is based on advanced patented technology, including an innovative methodology for measuring the tumor-initiating stem cell associated biomarker CD44, in combination with total protein. This clinically validated test enables early and more accurate detection of oral cancer, even before visual indicators.

OraMark science leverages more than a decade of clinical research conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

The simple, oral rinse procedure for the OraMark Test product line is
easy to administer and non-invasive for the patient.